Pre-treatment biopsychosocial predictors of chemotherapy-induced peripheral neuropathy trajectories in people with breast cancer
Year: 2026
Type: article
Abstract: Chemotherapy-induced peripheral neuropathy (CIPN) affects many people receiving taxane treatment for breast cancer. Symptom trajectories vary, with some recovering, and others experiencing persistent, or delayed worsening (coasting) symptoms. The prevalence and predictors of these trajectories remain unclear. This study identified the prevalence and biopsychosocial predictors of CIPN persistence, improvement, and coasting within 3 months post-treatment. This secondary analysis included participants treated with taxanes for stage I–III breast cancer who completed the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group–Neurotoxicity-4 (FACT/GOG-NTX-4) at baseline, post-chemotherapy, and 3 months later. A minimally important difference (MID) from baseline on the FACT/GOG-NTX-4 defined persistence, improvement, coasting, and no MID-CIPN (below the MID threshold at each assessment) trajectories. Baseline assessments included self-reported pain/well-being, sensory, balance, and lower limb physical functioning measures, and sociodemographic and treatment data were collected. Among 102 participants (51.57 ± 11.24 years), persistence occurred in 34.3%, improvement in 25.5%, coasting in 6.9%, and no MID-CIPN in 33.3%. Compared to no MID-CIPN, older age (OR = 1.120; 95% CI 1.026–1.222), higher expected pain (OR = 1.630; 95% CI 1.082–2.456), and cold hyperalgesia at the foot (OR = 1.130; 95% CI 1.018–1.254) predicted persistence. Greater fatigue predicted improvement (OR = 0.904; 95% CI 0.845–0.968). No predictors were identified for coasting. CIPN trajectories are heterogeneous. Age and pre-treatment pain expectations, cold hyperalgesia, and fatigue differentiate patients with persistent CIPN and those likely to improve from those with no CIPN. Early identification of individuals at risk for persistent neurotoxicity may support risk stratification and guide targeted supportive care strategies.
Source: Journal of Cancer Survivorship
Authors: Charles-Antoine Auger(Conceptualization, Formal analysis, Investigation, Methodology, Writing – original draft), Antoine Frasie(Conceptualization, Formal analysis, Investigation, Methodology, Writing – original draft), Maud Bouffard(Writing – original draft), Frédérique Therrien(Writing – original draft), Sarah Béland(Writing – original draft), Anne Dionne(Methodology, Writing – original draft), Robert H. Dworkin(Methodology, Writing – original draft), Lucia Gagliese(Conceptualization, Methodology, Writing – original draft), Jennifer S. Gewandter(Methodology, Writing – original draft), Philip L. Jackson(Methodology, Writing – original draft), Sophie Lauzier(Methodology, Writing – original draft), Julie Lemieux(Methodology, Writing – original draft), Josée Savard(Methodology, Writing – original draft), Lynn R. Gauthier(Conceptualization, Formal analysis, Investigation, Methodology, Writing – original draft)
Institutions: Michel-Sarrazin, Université Laval, Centre de recherche du CHU de Québec-Université Laval, Université du Québec à Trois-Rivières, Centre hospitalier universitaire de Québec, University of Rochester Medicine, University of Rochester, University of Toronto, York University, Sinai Health System, Centre interdisciplinaire de recherche en réadaptation et intégration sociale, Centre de recherche CERVO
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,790
OpenAlex ID: W7161483757
